Polyrizon Advances NASARIXTM Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIXTM allergy blocker’s protective barrier function